Inperium Announces its Affiliation with RHD to Expand its Human Services Networks
Ryan D. Smith, Executive Chairman and CEO of Inperium
Inperium, Inc., one of the country's fastest growing nonprofit human services networks, officially announces its affiliation with Resources for Human Development (RHD), a multi-state provider of behavioral health and social support services. The affiliation marks a significant milestone in the nonprofit sector, combining the strengths of both organizations and forming a network that spans 20 states and, according to the company, is expected to generate in excess of $800 million in annual revenue.
Under the new partnership, Inperium will integrate RHD into its national platform, investing in operational upgrades while preserving RHD's mission and local impact. The collaboration comes after a year-long turnaround effort led by Inperium through a Transitional Services Agreement, during which RHD's financial health was stabilized and operational inefficiencies were addressed.
'Too often, nonprofits expand beyond their core geography without the systems or infrastructure needed to scale sustainability,' said Ryan D. Smith, Executive Chairman and CEO of Inperium. 'RHD had strong roots and mission alignment, but like many others, they experienced the compounding effects of overexpansion, delayed tech upgrades, and rising operational costs; challenges that were intensified by COVID-19. We stepped in to provide bridge financing and implement structural reforms that would create long-term sustainability.'
Through its integration plan, Inperium executed a series of cost-saving measures, including the migration of RHD's health records and IT systems to Inperium's secure network, the consolidation of HR and accounting systems under a renowned multinational computer technology company, and the centralization of insurance and procurement services. These changes created operational efficiencies and significantly reduced overhead, allowing RHD to continue its mission without disruption.
Inperium's model, what Jay Deppeler, Chair RHD Board, describes as 'professionalizing without compromising', aims to support nonprofits in distress by providing the infrastructure, tools, and capital to thrive, without altering their core identity or community presence. 'Their approach involves strengthening local culture,' said Deppeler. 'They bring the behind-the-scenes support and financial discipline so these organizations can focus on what they do best: serving people.'
While Inperium's network includes nearly forty organizations across the United States, Smith shares that the company is intentionally keeping its focus domestic for now, despite interest in international expansion. 'We have the tools and capacity to evaluate thousands of nonprofits using real-time data,' said Smith, referencing Inperium's proprietary AI-driven assessment platform. 'But we're focused on supporting U.S.-based partners, especially those that are struggling and in need of strategic, values-aligned solutions.'
Jay Deppeler, Chair RHD Board
Deppeler concluded: 'Combining the RHD and Inperium service networks will enhance the continuum of care for the people we support. I commend and thank the RHD Board for the enormous energy and determination it invested to lead this transformational undertaking to a successful conclusion.'
This affiliation, one of four deals completed by Inperium in the first half of Fiscal Year 2025, is part of the organization's broader strategy to surpass a billion dollars in annualized revenue by 2026. As Smith noted, 'The nonprofit sector is facing unprecedented headwinds. The organizations that survive and thrive will be those willing to adapt and innovate without losing sight of their mission. That's what we're here to do.'
Media Contact
Name: Jennifer Gassen
Email: [email protected]
Source published by Submit Press Release >> Inperium Announces its Affiliation with RHD to Expand its Human Services Networks
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Guess? Inc. to go private in $1.4B acquisition
Guess? Inc., the Los Angeles-based fashion brand that specializes in denim, is going private in a $1.4-billion deal with Authentic Brands Group. Under the terms of the deal, the company's co-founders Maurice and Paul Marciano, as well as chief executive Carlos Alberini, will own 49% of its intellectual property. Authentic Brands Group will own 51%. Shares for Guess jumped more than 25% in midday trading on Wednesday. Shareholders will receive $16.75 per share in cash as a result of the sale, a 26% premium to the stock's closing price on Tuesday. Current Guess management will continue to run the business and own 100% of the operating company, Guess said in a release. "We look forward to building on the significant progress we have made to strengthen our organization," Alberini said in a statement. "As a private company benefiting from the perspectives of a globally recognized licensing partner, Guess? will have enhanced flexibility to navigate today's complex operating environment." Retailers have been squeezed by inflation, high labor costs and uncertainty stemming from President Trump's tariffs, experts said. Forever 21, another Los Angeles-based fashion company that once earned billions in revenue, filed for its second bankruptcy in six years in March. The chain is shutting down its U.S. stores. Department stores Macy's and Kohl's are also shuttering locations, while other companies are going private or consolidating. The sneakers brand Skechers was taken private in May in a $9.4-billion deal with New York investment firm 3G Capital. Also in May, Dick's Sporting Goods announced it would buy struggling footwear chain Foot Locker for $2.4 billion. The transaction between Guess and Authentic Brands Group is expected to close in the fourth quarter of Guess' 2026 fiscal year. Authentic Brands owns more than 50 global brands, generating approximately $32 billion in annual system-wide retail sales, the Guess release said. The group owns popular names in fashion and lifestyle, including Champion and Eddie Bauer. Guess was founded in 1981 by the Marciano brothers, who moved from France to Los Angeles to start their business. The company offers a range of clothing as well as accessories, including handbags and glasses. In the quarter ended May 3, Guess reported an increase in revenues to $648 million and estimated revenues would continue to increase between 5.5% and 7.4% for the rest of the fiscal year. Shares for the company have risen more than 21% this year. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Indianapolis Star
an hour ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
Yahoo
an hour ago
- Yahoo
New Covid wave warning as cases in hospital patients soar by 31% in a fortnight
Covid cases in hospital patients have jumped by almost a third in a fortnight - sparking concerns of a new Covid wave. The number of hospital patients with respiratory symptoms testing positive for the virus has increased from 5.8 per cent on 26 July to 7.6 per cent on 10 August, according to the UK Health Security Agency (UKHSA). That marks an increase of 31 per cent in just 15 days. This percentage is known as the positivity rate and it is much higher among hospital patients with symptoms than the general public. The rise in cases in hospitals could be an indication the country is facing a new wave of infections, with epidemiologists suggesting soaring cases could be a cause for concern. 'This rise in cases reinforces the fact that the virus is still circulating and is capable of spreading,' Professor Lawrence Young, a virologist at Warwick University told The Independent. He added: 'A particular concern is the impact on infection levels as people return to work and school after the holiday season and the effect of cooler weather. This coupled with new virus variants and restricted access to free vaccines over the Autumn period is worrying.' But experts stress it is difficult to get an accurate picture as people no longer routinely test for the virus. Infectious disease expert Professor Paul Hunter, at University of East Anglia, explained that infection numbers have been drifting up and down for most of the year and he expects cases to rise as we approach the end of the year. 'We will see further increases but against a continuing declining general trend in hospitalisation and deaths. As to how many infections are occurring in the community. I have no idea as we only really test people in hospitals now,' Professor Hunter told the Independent. 'As to how many infections are occurring in the community, I have no idea as we only really test people in hospital now,' he added. Although this spike of 7.6 per cent is still lower than it was for most of the pandemic, it's much higher than it was in January when it was 2.2 per cent. In July last year, cases hit 16.6 per cent and 14.6 per cent in October last year, according to UKHSA data. The Covid vaccine is usually offered on the NHS in spring and early winter to people who need extra protection from the virus. But this year almost 13 million fewer people will be offered the booster jab. The Government is no longer offering the jab to pensioners aged 65 to 74, nor are they offering it to pregnant women or people with chronic heart disease or liver disease. This autumn the vaccine will be offered to adults over 75, residents in care homes for older adults and those who are immunosuppressed over the age of six months.
